Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:58 pm
| PEG Ratio | 0.32 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd operates within the pharmaceuticals sector and reported a current price of ₹103 with a market capitalization of ₹759 Cr. The company has demonstrated fluctuating revenue trends, with sales reported at ₹1,207 Cr for the financial year ending March 2023, a significant increase from ₹1,039 Cr in the previous year. However, sales projections for March 2025 indicate a decline to ₹562 Cr, suggesting potential challenges ahead. Quarterly sales figures reflect this volatility, with the highest quarterly sales of ₹528.57 Cr recorded in March 2024, followed by a sharp drop to ₹33.17 Cr in June 2024. The company’s operating profit margin (OPM) stood at 2.36% for the most recent period, indicating tight control over costs but also raising questions about overall operational efficiency compared to industry averages, which typically range higher. The company’s reliance on a narrow revenue base could be a concern as market conditions fluctuate.
Profitability and Efficiency Metrics
Ind-Swift Laboratories reported a net profit of ₹226 Cr, translating to a price-to-earnings (P/E) ratio of 34.4, which is relatively high and may suggest overvaluation compared to industry norms. The return on equity (ROE) stood at 18%, while the return on capital employed (ROCE) was recorded at 0.78%, both metrics indicating subpar profitability relative to typical sector benchmarks. The operating profit for the financial year March 2024 was ₹306 Cr, reflecting a significant increase from ₹229 Cr in March 2023, yet the company faced challenges in maintaining consistent profitability as indicated by a decline to negative operating profit margins in subsequent periods. The interest coverage ratio (ICR) was a concerning 0.10x, signaling potential difficulties in meeting interest obligations, a critical risk factor that could affect future financing options and operational stability.
Balance Sheet Strength and Financial Ratios
Ind-Swift Laboratories’ balance sheet reflects a total equity capital of ₹69 Cr and reserves of ₹1,104 Cr, showcasing a solid equity base. The company’s total borrowings significantly decreased to ₹41 Cr by March 2025, down from ₹862 Cr in March 2023, which indicates a substantial reduction in leverage and improved financial health. The current ratio stood at 3.92, significantly above the typical threshold of 2, suggesting strong liquidity and the ability to cover short-term liabilities. However, the price-to-book value ratio (P/BV) at 0.49x indicates that the market may undervalue the stock compared to its net asset value. This discrepancy could be an opportunity for investors, yet it also raises questions about the market’s perception of the company’s future growth prospects. The erosion of the asset turnover ratio to 0.14% also signals inefficiencies in asset utilization, further complicating the financial outlook.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ind-Swift Laboratories reveals a gradual shift in ownership dynamics. Promoters held 39.49% of the company as of recent filings, down from 42.01% at the beginning of 2023, signaling a potential reduction in insider confidence. Foreign Institutional Investors (FIIs) have increased their stake to 14.90%, a significant rise from 0.04% in December 2022, reflecting growing interest from overseas investors. Conversely, Domestic Institutional Investors (DIIs) have reduced their holdings to 0.68%, down from 19.49%, which may indicate a lack of confidence among domestic institutional players. The total number of shareholders increased to 43,984, which could imply growing retail investor interest. However, the declining promoter stake alongside reduced institutional confidence may pose risks to stock stability and future governance.
Outlook, Risks, and Final Insight
Looking ahead, Ind-Swift Laboratories faces both opportunities and challenges. The company’s reduced borrowings and strong liquidity position provide a foundation for potential growth initiatives. However, the volatility in sales and profitability metrics indicates significant operational risks. The high P/E ratio suggests that the stock may be overvalued given its inconsistent earnings performance. Additionally, the declining shareholding by promoters could signal underlying concerns about future prospects. Investors should remain vigilant regarding market conditions and operational efficiencies, as these factors will be pivotal for the company’s recovery and growth. If Ind-Swift Laboratories can stabilize its revenue streams and enhance its operational efficiency, it may present a compelling investment opportunity. Conversely, continued fluctuations in profitability and investor sentiment could hinder its market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ind-Swift Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 33.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,079 Cr. | 464 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.1 Cr. | 24.0 | 29.1/17.0 | 36.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,966.35 Cr | 1,197.73 | 54.46 | 195.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 280.17 | 310.21 | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 124.66 | 138.24 | 152.73 |
| Expenses | 227.16 | 251.45 | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 131.31 | 147.44 | 149.13 |
| Operating Profit | 53.01 | 58.76 | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 |
| OPM % | 18.92% | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.33% | -6.66% | 2.36% |
| Other Income | 7.39 | 7.54 | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 |
| Interest | 23.98 | 23.98 | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 |
| Depreciation | 16.28 | 16.41 | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 |
| Profit before tax | 20.14 | 25.91 | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 |
| Tax % | 1.09% | 2.16% | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% |
| Net Profit | 19.88 | 25.34 | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 |
| EPS in Rs | 3.36 | 4.29 | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 152.73 Cr.. The value appears strong and on an upward trend. It has increased from 138.24 Cr. (Mar 2025) to 152.73 Cr., marking an increase of 14.49 Cr..
- For Expenses, as of Jun 2025, the value is 149.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 147.44 Cr. (Mar 2025) to 149.13 Cr., marking an increase of 1.69 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.60 Cr.. The value appears strong and on an upward trend. It has increased from -9.20 Cr. (Mar 2025) to 3.60 Cr., marking an increase of 12.80 Cr..
- For OPM %, as of Jun 2025, the value is 2.36%. The value appears strong and on an upward trend. It has increased from -6.66% (Mar 2025) to 2.36%, marking an increase of 9.02%.
- For Other Income, as of Jun 2025, the value is 14.58 Cr.. The value appears to be declining and may need further review. It has decreased from 220.34 Cr. (Mar 2025) to 14.58 Cr., marking a decrease of 205.76 Cr..
- For Interest, as of Jun 2025, the value is 1.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -26.76 Cr. (Mar 2025) to 1.15 Cr., marking an increase of 27.91 Cr..
- For Depreciation, as of Jun 2025, the value is 6.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.44 Cr. (Mar 2025) to 6.68 Cr., marking a decrease of 0.76 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.35 Cr.. The value appears to be declining and may need further review. It has decreased from 230.46 Cr. (Mar 2025) to 10.35 Cr., marking a decrease of 220.11 Cr..
- For Tax %, as of Jun 2025, the value is 16.52%. The value appears to be increasing, which may not be favorable. It has increased from 3.55% (Mar 2025) to 16.52%, marking an increase of 12.97%.
- For Net Profit, as of Jun 2025, the value is 8.77 Cr.. The value appears to be declining and may need further review. It has decreased from 222.27 Cr. (Mar 2025) to 8.77 Cr., marking a decrease of 213.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 36.67 (Mar 2025) to 1.45, marking a decrease of 35.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,709 | 562 | 428 |
| Expenses | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,403 | 581 | 452 |
| Operating Profit | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 306 | -19 | -24 |
| OPM % | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 18% | -3% | -6% |
| Other Income | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 476 | 305 | 264 |
| Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 104 | 3 | -15 |
| Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 80 | 24 | 20 |
| Profit before tax | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 598 | 258 | 235 |
| Tax % | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 10% | 3% | |
| Net Profit | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 539 | 250 | 226 |
| EPS in Rs | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 91.18 | 41.32 | 37.26 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 1022.92% | -53.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1477.08% | -1076.53% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:15 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,104.00 Cr.. The value appears strong and on an upward trend. It has increased from 745.00 Cr. (Mar 2024) to 1,104.00 Cr., marking an increase of 359.00 Cr..
- For Borrowings, as of Mar 2025, the value is 41.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 217.00 Cr. (Mar 2024) to 41.00 Cr., marking a decrease of 176.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 224.00 Cr.. The value appears to be improving (decreasing). It has decreased from 432.00 Cr. (Mar 2024) to 224.00 Cr., marking a decrease of 208.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 273.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 273.00 Cr., marking an increase of 81.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 51.00 Cr..
- For Investments, as of Mar 2025, the value is 213.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Mar 2024) to 213.00 Cr., marking an increase of 101.00 Cr..
- For Other Assets, as of Mar 2025, the value is 952.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,106.00 Cr. (Mar 2024) to 952.00 Cr., marking a decrease of 154.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
Notably, the Reserves (1,104.00 Cr.) exceed the Borrowings (41.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 89.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 32.54 | 71.24 | 8.10 | -0.36 | -0.53 |
| Diluted EPS (Rs.) | 32.53 | 71.24 | 8.10 | -0.36 | -0.53 |
| Cash EPS (Rs.) | 33.72 | 80.35 | 17.59 | 21.55 | 14.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 170.63 | 157.64 | 83.36 | 67.61 | 65.66 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 170.63 | 157.64 | 114.02 | 100.47 | 100.90 |
| Revenue From Operations / Share (Rs.) | 27.93 | 216.78 | 201.87 | 173.68 | 149.04 |
| PBDIT / Share (Rs.) | -0.41 | 50.70 | 43.92 | 39.98 | 34.36 |
| PBIT / Share (Rs.) | -1.60 | 41.68 | 34.33 | 18.07 | 19.77 |
| PBT / Share (Rs.) | 33.59 | 98.46 | 14.47 | 2.10 | 3.01 |
| Net Profit / Share (Rs.) | 32.54 | 71.33 | 8.00 | -0.35 | -0.52 |
| NP After MI And SOA / Share (Rs.) | 32.53 | 71.24 | 7.96 | -0.35 | -0.52 |
| PBDIT Margin (%) | -1.48 | 23.38 | 21.75 | 23.01 | 23.05 |
| PBIT Margin (%) | -5.72 | 19.22 | 17.00 | 10.40 | 13.26 |
| PBT Margin (%) | 120.26 | 45.41 | 7.16 | 1.20 | 2.02 |
| Net Profit Margin (%) | 116.48 | 32.90 | 3.96 | -0.20 | -0.35 |
| NP After MI And SOA Margin (%) | 116.45 | 32.86 | 3.94 | -0.20 | -0.35 |
| Return on Networth / Equity (%) | 19.06 | 45.19 | 9.54 | -0.53 | -0.80 |
| Return on Capital Employeed (%) | -0.90 | 26.09 | 14.13 | 7.36 | 7.86 |
| Return On Assets (%) | 15.54 | 36.13 | 2.60 | -0.11 | -0.17 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 1.51 | 2.10 | 2.25 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 1.73 | 2.35 | 2.56 |
| Asset Turnover Ratio (%) | 0.14 | 0.85 | 0.66 | 0.54 | 0.46 |
| Current Ratio (X) | 3.92 | 2.99 | 3.14 | 3.22 | 3.00 |
| Quick Ratio (X) | 3.41 | 2.94 | 1.96 | 1.94 | 1.81 |
| Inventory Turnover Ratio (X) | 3.08 | 2.67 | 1.52 | 1.33 | 1.23 |
| Interest Coverage Ratio (X) | 0.10 | 5.86 | 2.85 | 2.50 | 2.05 |
| Interest Coverage Ratio (Post Tax) (X) | 0.70 | 1.68 | 1.81 | 0.97 | 0.96 |
| Enterprise Value (Cr.) | 121.62 | 165.50 | 1173.71 | 1328.01 | 1424.06 |
| EV / Net Operating Revenue (X) | 0.98 | 0.12 | 0.97 | 1.28 | 1.60 |
| EV / EBITDA (X) | -66.67 | 0.55 | 4.47 | 5.55 | 6.93 |
| MarketCap / Net Operating Revenue (X) | 3.01 | 0.45 | 0.27 | 0.38 | 0.48 |
| Price / BV (X) | 0.49 | 0.62 | 0.66 | 0.98 | 1.10 |
| Price / Net Operating Revenue (X) | 3.01 | 0.45 | 0.27 | 0.38 | 0.48 |
| EarningsYield | 0.38 | 0.72 | 0.14 | -0.01 | -0.01 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 32.54. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.54, marking a decrease of 38.70.
- For Diluted EPS (Rs.), as of Mar 25, the value is 32.53. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.53, marking a decrease of 38.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 33.72. This value is within the healthy range. It has decreased from 80.35 (Mar 24) to 33.72, marking a decrease of 46.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.63. It has increased from 157.64 (Mar 24) to 170.63, marking an increase of 12.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.63. It has increased from 157.64 (Mar 24) to 170.63, marking an increase of 12.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 27.93. It has decreased from 216.78 (Mar 24) to 27.93, marking a decrease of 188.85.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.41. This value is below the healthy minimum of 2. It has decreased from 50.70 (Mar 24) to -0.41, marking a decrease of 51.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.60. This value is below the healthy minimum of 0. It has decreased from 41.68 (Mar 24) to -1.60, marking a decrease of 43.28.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.59. This value is within the healthy range. It has decreased from 98.46 (Mar 24) to 33.59, marking a decrease of 64.87.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 32.54. This value is within the healthy range. It has decreased from 71.33 (Mar 24) to 32.54, marking a decrease of 38.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.53. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 32.53, marking a decrease of 38.71.
- For PBDIT Margin (%), as of Mar 25, the value is -1.48. This value is below the healthy minimum of 10. It has decreased from 23.38 (Mar 24) to -1.48, marking a decrease of 24.86.
- For PBIT Margin (%), as of Mar 25, the value is -5.72. This value is below the healthy minimum of 10. It has decreased from 19.22 (Mar 24) to -5.72, marking a decrease of 24.94.
- For PBT Margin (%), as of Mar 25, the value is 120.26. This value is within the healthy range. It has increased from 45.41 (Mar 24) to 120.26, marking an increase of 74.85.
- For Net Profit Margin (%), as of Mar 25, the value is 116.48. This value exceeds the healthy maximum of 10. It has increased from 32.90 (Mar 24) to 116.48, marking an increase of 83.58.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 116.45. This value exceeds the healthy maximum of 20. It has increased from 32.86 (Mar 24) to 116.45, marking an increase of 83.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.06. This value is within the healthy range. It has decreased from 45.19 (Mar 24) to 19.06, marking a decrease of 26.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.90. This value is below the healthy minimum of 10. It has decreased from 26.09 (Mar 24) to -0.90, marking a decrease of 26.99.
- For Return On Assets (%), as of Mar 25, the value is 15.54. This value is within the healthy range. It has decreased from 36.13 (Mar 24) to 15.54, marking a decrease of 20.59.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.14. It has decreased from 0.85 (Mar 24) to 0.14, marking a decrease of 0.71.
- For Current Ratio (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 3.92, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 2. It has increased from 2.94 (Mar 24) to 3.41, marking an increase of 0.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 4. It has increased from 2.67 (Mar 24) to 3.08, marking an increase of 0.41.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 3. It has decreased from 5.86 (Mar 24) to 0.10, marking a decrease of 5.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 3. It has decreased from 1.68 (Mar 24) to 0.70, marking a decrease of 0.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 121.62. It has decreased from 165.50 (Mar 24) to 121.62, marking a decrease of 43.88.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.12 (Mar 24) to 0.98, marking an increase of 0.86.
- For EV / EBITDA (X), as of Mar 25, the value is -66.67. This value is below the healthy minimum of 5. It has decreased from 0.55 (Mar 24) to -66.67, marking a decrease of 67.22.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has increased from 0.45 (Mar 24) to 3.01, marking an increase of 2.56.
- For Price / BV (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 24) to 0.49, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has increased from 0.45 (Mar 24) to 3.01, marking an increase of 2.56.
- For EarningsYield, as of Mar 25, the value is 0.38. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.38, marking a decrease of 0.34.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 116.48%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.9% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.06% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.1 (Industry average Stock P/E: 54.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 116.48%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | investor@indswiftlabs.com http://www.indswiftlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. S P Sharma | Independent Director |
| Mr. Param Bir Singh | Independent Director |
| Dr. Ashwani Kumar Vig | Independent Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 03 November 2025) is 9.72 which is 90.47% lower the current market price of 102.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 751 Cr. market cap, FY2025-2026 high/low of 124/67.2, reserves of ₹1,104 Cr, and liabilities of 1,438 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 751 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 03 November 2025?
The current stock price of Ind-Swift Laboratories Ltd as on 03 November 2025 is 102.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is 124/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 34.1.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 194.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.